
NEW ORLEANS, LA – The U.S. Fifth Circuit Court of Appeals ruled that the Food and Drug Administration (FDA) improperly expanded access to the chemical abortion pill mifepristone over the last seven years and reimposed restrictions that doctors only must be in person for dispensing the drug mifepristone.
In Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration, the three-judge panel said that the medical professionals who sued the FDA had likely waited too long to challenge the drug’s original approval in 2000, and it also left in place the agency’s 2019 approval of the generic version of the pill. Yet the appeals court stated the FDA failed to properly scrutinize changes that increased access to mifepristone in recent years, such as allowing the drug to be administered without an in-person visit with a medical provider, including by mail.
